Imagion Biosystems (ASX:IBX) raises A$3.75m at a 24% discount to start dosing

The IND clearance brought the cheque, and Part A enrolment now decides the next 18 months

Imagion Biosystems (ASX:IBX) has secured A$3.75 million of firm commitments to fund the start of its Phase 1b/2 trial of the MagSense HER2 imaging agent. The raise is structured as a two-tranche placement at 1.2 cents per share, a 24.32% discount to the 10-day VWAP. Each two new shares come with one free attaching IBXO listed option exercisable at 4 cents and expiring in December 2027.

CPS Capital led the placement, and Executive Chairman Bob Proulx flagged that demand exceeded expectations following last month’s FDA Study May Proceed Notice on IND 165081. Directors and management have committed up to A$100,000 of their own money, subject to the August EGM.

For a company that has spent nine years on the ASX waiting for a real clinical readout, this is the cheque that turns the regulatory green light into actual patient enrolment. The capital is small, the dilution is real, and the trial economics are now the story. We think the more interesting question is what A$3.75 million actually buys at this stage of a multi-part US trial.

The raise covers Part A, not the whole trial

The placement is sized to fund trial initiation, first patient dosed, and completion of the first cohort. That maps to Part A of the three-part Phase 1b/2 design, which is the additional safety stage before the optimised-dose Part B and the larger diagnostic-performance Part C.

In plain English, this money gets MagSense into the first group of HER2-positive breast cancer patients and produces an interim safety readout. It does not get the company to the final efficacy data that establishes diagnostic performance.

Investors should assume at least one more raise before Part C completes. The 4 cent listed options provide a path to that capital if the Part A and Part B readouts go well, but if they don’t, the next raise will look a lot uglier than this one.

The 24% discount tells you who has pricing power right now

A 24.32% discount to VWAP, plus one free option for every two shares, is not the pricing of a company with leverage over its capital providers. It is the pricing of a clinical-stage micro-cap that needed the cash and needed it now to keep the trial timeline intact.

The skeptical read is that the FDA clearance moved the science forward but did not yet move the share price into a range where the company could raise on better terms. The constructive read is that sophisticated investors took the deal anyway, which suggests they see the Part A readout as a genuine re-rating event.

Both reads can be true. The dilution today is the price of buying the chance for a much higher share price 12 to 18 months from now.

What changes operationally from here

Trial activation has already started. Site contracting at City of Hope in Los Angeles is underway with Dr Eghtedari as principal investigator, and patient recruitment is targeted for Q3 2026, which is the next quarter.

The proceeds also fund ongoing manufacturing of the MagSense agent and continued work on quantitative MRI techniques and AI-based modelling. That last piece matters because the commercial pitch is not just better contrast on a scan, it is a measurable, software-supported diagnostic output that radiologists can act on.

The Investors Takeaway for Imagion Biosystems

Imagion’s investment case has shifted in the last two months. The FDA clearance removed regulatory risk, and this placement removes near-term funding risk for Part A. What remains is the hardest part, which is generating clinical data that institutions and potential partners will actually pay attention to.

We think the share price between now and the Part A readout will be driven almost entirely by enrolment cadence and any commentary from City of Hope on early safety. Investors holding through dilution are effectively buying optionality on that interim data, with the 4 cent listed options as a second swing if the story holds. Our previous coverage of the FDA clearance is at stocksdownunder for the regulatory backdrop.